Although many promising molecules are regularly identified as potentially effective in the treatment of MS, their therapeutic potential is frequently limited by low accumulation in the central nervous system. The purpose of this project is therefore to develop nanoparticles which protect these molecules and enable them to be specifically delivered to the cells involved in remyelination. Moreover, they can be administered to patients in a non-invasive manner, e.g. nasally.